Return to Clinical Trials Search Results

MK6482-011 An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy

Primary Objective: -To compare MK- 6482+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). -Hypothesis (H1): MK-6482+lenvatinib is superior to cabozantinib with respect to PFS per RECIST 1.1 by BICR. -To compare MK-6482+lenvatinib to cabozantinib with respect to OS. -Hypothesis (H2): MK-6482+lenvatinib is superior to cabozantinib with respect to OS.

Primary Objective: -To compare MK- 6482+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). -Hypothesis (H1): MK-6482+lenvatinib is superior to cabozantinib with respect to PFS per RECIST 1.1 by BICR. -To compare MK-6482+lenvatinib to cabozantinib with respect to OS. -Hypothesis (H2): MK-6482+lenvatinib is superior to cabozantinib with respect to OS.